TISIDB

Summary
Symbol	MRC1
Name	mannose receptor, C type 1
Aliases	CLEC13D; CD206; bA541I19.1; CLEC13DL; MRC1L1; mannose receptor, C type 1-like 1; MMRL1; C-type lectin domain ......
Chromosomal Location	10p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Endosome membrane Single-pass type I membrane protein Cell membrane Single-pass type I membrane protein
Domain	PF00040 Fibronectin type II domain PF00059 Lectin C-type domain PF00652 Ricin-type beta-trefoil lectin domain
Function	Mediates the endocytosis of glycoproteins by macrophages. Binds both sulfated and non-sulfated polysaccharide chains.; FUNCTION: (Microbial infection) Acts as phagocytic receptor for bacteria, fungi and other pathogens.; FUNCTION: (Microbial infection) Acts as a receptor for Dengue virus envelope protein E. ; FUNCTION: (Microbial infection) Interacts with Hepatitis B virus envelope protein.

> Gene Ontology [ TOP ]
Biological Process	GO:0002237 response to molecule of bacterial origin GO:0006898 receptor-mediated endocytosis GO:0019058 viral life cycle GO:0030260 entry into host cell GO:0032496 response to lipopolysaccharide GO:0034341 response to interferon-gamma GO:0044409 entry into host GO:0046718 viral entry into host cell GO:0051701 interaction with host GO:0051806 entry into cell of other organism involved in symbiotic interaction GO:0051828 entry into other organism involved in symbiotic interaction GO:0070670 response to interleukin-4 GO:0071216 cellular response to biotic stimulus GO:0071219 cellular response to molecule of bacterial origin GO:0071222 cellular response to lipopolysaccharide GO:0071346 cellular response to interferon-gamma GO:0071353 cellular response to interleukin-4 GO:0071396 cellular response to lipid
Molecular Function	GO:0001618 virus receptor activity GO:0005537 mannose binding GO:0030246 carbohydrate binding GO:0048029 monosaccharide binding
Cellular Component	GO:0010008 endosome membrane GO:0044440 endosomal part

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04145 Phagosome
Reactome	R-HSA-1280218: Adaptive Immune System R-HSA-1236975: Antigen processing-Cross presentation R-HSA-983169: Class I MHC mediated antigen processing & presentation R-HSA-1236978: Cross-presentation of soluble exogenous antigens (endosomes) R-HSA-168256: Immune System

Summary
Symbol	MRC1
Name	mannose receptor, C type 1
Aliases	CLEC13D; CD206; bA541I19.1; CLEC13DL; MRC1L1; mannose receptor, C type 1-like 1; MMRL1; C-type lectin domain ......
Chromosomal Location	10p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between MRC1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between MRC1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
21523763	Pleural Malignant Mesothelioma	Inhibit immunity	Within MPM tumors, macrophages comprised 27% ± 9% of the tumor area and demonstrated an immunosuppressive phenotype with high expression of CD163, CD206, and interleukin-4 receptor α.
23271806	Lung Carcinoma; Mesothelioma	Inhibit immunity	Recurrent tumors and draining lymph nodes are infiltrated with M2 (CD11b+F4/80hiCD206hi and CD11b+F4/80hiCD124hi) macrophages and CD4+Foxp3+ regulatory T cells. This complex network of immunosuppression in the surrounding tumor microenvironment explains the resistance of tumor recurrences to conventional cancer vaccines despite small tumor size, an intact antitumor immune response, and unaltered cancer cells.

Summary
Symbol	MRC1
Name	mannose receptor, C type 1
Aliases	CLEC13D; CD206; bA541I19.1; CLEC13DL; MRC1L1; mannose receptor, C type 1-like 1; MMRL1; C-type lectin domain ......
Chromosomal Location	10p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of MRC1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	MRC1
Name	mannose receptor, C type 1
Aliases	CLEC13D; CD206; bA541I19.1; CLEC13DL; MRC1L1; mannose receptor, C type 1-like 1; MMRL1; C-type lectin domain ......
Chromosomal Location	10p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of MRC1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.703	0.147
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.908	0.378
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.549	0.491
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.437	0.735
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.029	0.989
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	1	0.628
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.235	0.672
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.274	0.89
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.22	0.921
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0	1
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0	1
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.396	0.0292

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of MRC1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	5.9	-1.1	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	9.1	-1.4	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	MRC1
Name	mannose receptor, C type 1
Aliases	CLEC13D; CD206; bA541I19.1; CLEC13DL; MRC1L1; mannose receptor, C type 1-like 1; MMRL1; C-type lectin domain ......
Chromosomal Location	10p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MRC1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	MRC1
Name	mannose receptor, C type 1
Aliases	CLEC13D; CD206; bA541I19.1; CLEC13DL; MRC1L1; mannose receptor, C type 1-like 1; MMRL1; C-type lectin domain ......
Chromosomal Location	10p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MRC1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MRC1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	MRC1
Name	mannose receptor, C type 1
Aliases	CLEC13D; CD206; bA541I19.1; CLEC13DL; MRC1L1; mannose receptor, C type 1-like 1; MMRL1; C-type lectin domain ......
Chromosomal Location	10p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MRC1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	MRC1
Name	mannose receptor, C type 1
Aliases	CLEC13D; CD206; bA541I19.1; CLEC13DL; MRC1L1; mannose receptor, C type 1-like 1; MMRL1; C-type lectin domain ......
Chromosomal Location	10p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of MRC1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	MRC1
Name	mannose receptor, C type 1
Aliases	CLEC13D; CD206; bA541I19.1; CLEC13DL; MRC1L1; mannose receptor, C type 1-like 1; MMRL1; C-type lectin domain ......
Chromosomal Location	10p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between MRC1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	MRC1
Name	mannose receptor, C type 1
Aliases	CLEC13D; CD206; bA541I19.1; CLEC13DL; MRC1L1; mannose receptor, C type 1-like 1; MMRL1; C-type lectin domain ......
Chromosomal Location	10p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting MRC1 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting MRC1.

ID	Name	Drug Type	Targets	#Targets
DB09266	Technetium Tc-99m tilmanocept	Small Molecule	MRC1	1

Browse MRC1